Regenxbio Inc

+0.44 (+0.99%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)1.92B
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$33.17 Million
Adjusted EPS-$1.04
See more estimates
10-Day MA$40.62
50-Day MA$34.43
200-Day MA$38.35
See more pivots

Regenxbio Inc Stock, NASDAQ:RGNX

9804 Medical Center Drive, Suite 210, Rockville, Maryland 20850
United States of America
Phone: +1.240.552.8181
Number of Employees: 306


REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. Its product candidates include NAV Technology Platform, which consists of exclusive rights to novel adeno-associated viral vectors; and therapeutic programs such as RGX-314, RGX-202, RGX-121, RGX-111, RGX-181, and RGX-381. The company was founded by Kenneth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.